Defined by massive calcium influx activating phospholipases/proteases, plasma/lysosomal membrane rupture, and mitochondrial permeability transition (cytochrome c release).
Coagulative necrosis preserves tissue architecture in solid-organ ischemia (heart, kidney, spleen); Liquefactive necrosis occurs in brain infarcts and bacterial abscesses.
Intrinsic (BCL-2/BAX mitochondrial cytochrome c -> Caspase-9) and Extrinsic (FasL-Fas / TNF -> Caspase-8) pathways converge on Caspase-3/7 DNA laddering (180 bp) without inflammation.
Extracellular beta-pleated sheet fibrils stain salmon-pink on H&E and exhibit apple-green birefringence under polarized light with Congo red stain.
Tumor suppressor genes (RB1, TP53, APC, VHL, BRCA1/2) require biallelic loss of function; proto-oncogenes (RAS, MYC, HER2, BCL-2, BCR-ABL) require only a single gain-of-function hit.
Holds cells at the G1/S checkpoint via p21 (inhibiting CDK4/Cyclin D phosphorylation of Rb); germline TP53 mutation causes Li-Fraumeni syndrome (SBLA).
Granulation tissue deposits Type III collagen (days 3–5), which zinc-dependent matrix metalloproteinases remodel into high-tensile Type I collagen (scar max 80% strength).
Neuroendocrine Kulchitsky tumor causing SIADH (ADH), Cushing syndrome (ectopic ACTH), and Lambert-Eaton Myasthenic Syndrome (presynaptic P/Q-type VGCC antibodies).
Cellular Adaptations, Reversible vs. Irreversible Injury & Free Radical Toxicity
Cells respond to physiologic stressors or pathologic stimuli by undergoing reversible structural adaptations—hypertrophy (increased cell size via gene transcription and myofibrillar synthesis; required in permanent non-dividing tissues such as myocardium, skeletal muscle, and neurons), hyperplasia (increased cell number via stem-cell mitosis; driven by hormones or growth factors in labile/stable tissues such as endometrium, benign prostatic hyperplasia, and bone marrow), atrophy (decreased cell size and number via the ubiquitin-proteasome pathway and autophagic vacuoles due to denervation, disuse, ischemia, or loss of trophic hormone stimulation), and metaplasia (reversible reprogramming of surface stem cells from one differentiated adult cell type to another better suited to withstand chronic irritation, exemplified by nonkeratinizing stratified squamous epithelium reprogramming into intestinal-type mucin-producing columnar epithelium with goblet cells in Barrett esophagus).
When stress exceeds adaptive capacity—most commonly from hypoxia (decreased oxygen delivery due to anemia, CO poisoning, or cardiorespiratory failure) or ischemia (compromised arterial inflow or venous outflow, which injures tissue faster than hypoxia alone because glycolytic substrates are depleted and toxic lactic acid accumulates)—the cell enters reversible injury followed by irreversible cell death.
| Pathologic Process | Primary Molecular Trigger | Key Ultrastructural / Microscopic Hallmarks | Reversibility Status | Classic Clinical / Board Correlate |
|---|---|---|---|---|
| Metaplasia vs. Dysplasia | Metaplasia: Stem-cell transcriptional reprogramming | Dysplasia: Disordered clonal proliferation | Metaplasia: Uniform mature cells of new lineage | Dysplasia: Pleomorphism, hyperchromatic nuclei, loss of polarity | Both are reversible if inciting stimulus is removed before basement membrane invasion | Barrett esophagus (squamous -> intestinal columnar with goblet cells -> adenocarcinoma); Smoking -> squamous metaplasia of bronchi |
| Reversible Cell Injury | Acute ATP depletion -> Na+/K+-ATPase pump failure & anaerobic glycolysis | Cellular/mitochondrial swelling, plasma membrane blebbing, ER dilation, ribosomal detachment, chromatin clumping | 100% Reversible upon restoration of oxygen and perfusion | Transient myocardial ischemia (angina pectoris) without troponin elevation |
| Irreversible Cell Injury | Massive Ca2+ influx -> phospholipase/protease/endonuclease activation + mitochondrial permeability pore | Plasma membrane discontinuity, lysosomal rupture, mitochondrial amorphous densities, nuclear pyknosis -> karyorrhexis -> karyolysis | Irreversible (culminates in necrosis or apoptosis) | Acute myocardial infarction with cytosolic leakage of cardiac troponin I/T and CK-MB |
| Ischemia-Reperfusion Injury | Reoxygenation of injured mitochondria + recruited neutrophils -> superoxide, H2O2, and hydroxyl (OH*) free radicals | Lipid peroxidation of membranes, contraction band necrosis in reperfused myocardium | Amplifies irreversible necrosis in borderline ischemic penumbra | Post-PCI reperfusion arrhythmias and continued troponin rise after STEMI revascularization |
| Dystrophic vs. Metastatic Calcification | Dystrophic: Necrotic tissue with NORMAL serum Ca2+ | Metastatic: Normal tissue with HYPERCALCEMIA | Dystrophic: Basophilic calcium granules + psammoma bodies | Metastatic: Interstitial calcium in acid-secreting tissues | Permanent mineral deposition on histology | Dystrophic: Calcific aortic stenosis, TB granulomas, Psammoma bodies (Papillary thyroid, Serous ovarian, Meningioma, Mesothelioma) | Metastatic: Nephrocalcinosis in hyperparathyroidism |
Biochemical Sequence of Reversible vs. Irreversible Ischemic Cell Injury
The initial event in ischemic/hypoxic injury is loss of mitochondrial oxidative phosphorylation and depletion of intracellular ATP. Within minutes, three reversible consequences ensue: (1) failure of the ATP-dependent Na+/K+-ATPase pump causes intracellular Na+, Cl-, and H2O accumulation, producing cellular and organelle hydropic swelling, endoplasmic reticulum dilation with detachment of ribosomes (halting protein synthesis), and plasma membrane blebbing with loss of microvilli; (2) failure of the Ca2+-ATPase pump initiates cytosolic calcium rise; and (3) compensatory shift to anaerobic glycolysis depletes glycogen stores and accumulates lactic acid, lowering intracellular pH and causing nuclear chromatin clumping. The transition to irreversible cell injury is defined by three lethal checkpoints: (1) severe plasma membrane rupture (releasing intracellular diagnostic biomarkers such as cardiac troponin I/T or hepatic AST/ALT into the bloodstream), (2) mitochondrial permeability transition pore opening with leakage of cytochrome c into the cytosol and formation of amorphous mitochondrial matrix densities, and (3) massive intracellular calcium (Ca2+) influx, which activates destructive calcium-dependent enzymes (phospholipases that degrade membranes, proteases that cleave the cytoskeleton, endonucleases that cause nuclear pyknosis [shrinkage], karyorrhexis [fragmentation], and karyolysis [dissolution], and ATPases), compounded by lysosomal rupture and autolysis.
Ischemia-Reperfusion Injury, Free Radicals & Intracellular Accumulations
Paradoxically, restoring blood flow to ischemic myocardium or brain triggers ischemia-reperfusion injury—causing a secondary surge in cell death and a continued rise in serum troponin or CK-MB—driven by mitochondrial generation of reactive oxygen species (ROS) (superoxide O2-, hydrogen peroxide H2O2, and hydroxyl radical OH• generated via the iron-catalyzed Fenton reaction), neutrophil infiltration, and complement activation. Free radicals peroxidize membrane lipids and oxidize proteins/DNA (classic in carbon tetrachloride [CCl4] hepatotoxicity, where CYP2E1 converts CCl4 into the CCl3• free radical, causing rough ER swelling, loss of apolipoprotein B synthesis, and hepatic fatty change [steatosis], as well as in retinopathy of prematurity and iron/copper overload). Cells neutralize ROS via enzymatic antioxidants (superoxide dismutase, catalase, and glutathione peroxidase) and non-enzymatic scavengers (Vitamins A, C, and E). Chronic sublethal injury also produces characteristic intracellular pigments: lipofuscin (“wear-and-tear” yellow-brown perinuclear pigment from lipid peroxidation in aging heart and liver) and hemosiderin (Prussian blue-positive golden-brown iron-ferritin aggregates seen in alveolar macrophages [“heart failure cells”] during chronic left-sided heart failure or hereditary hemochromatosis).
Six Morphologic Patterns of Necrosis vs. Intrinsic & Extrinsic Apoptosis
Irreversible cell death proceeds via two fundamentally distinct pathways: Necrosis (always a pathologic, messy, ATP-depleted process in which enzymatic digestion and plasma membrane rupture spill intracellular damage-associated molecular patterns [DAMPs], eliciting a brisk acute inflammatory neutrophil response) versus Apoptosis (an ATP-dependent, genetically programmed cell suicide executed by cysteine-aspartic proteases [caspases] in which the cell shrinks into eosinophilic apoptotic bodies with intact plasma membranes that are rapidly phagocytosed by macrophages with zero surrounding inflammation).
On histopathology and board vignettes, necrotic tissue exhibits six classic morphologic patterns determined by the balance between protein denaturation and enzymatic proteolysis: Coagulative, Liquefactive, Caseous, Fat, Fibrinoid, and Gangrenous necrosis.
| Necrosis / Cell Death Pattern | Prototypical Organ / Disease | Pathophysiologic Mechanism | Gross & Microscopic Appearance | Board Diagnostic Pearl |
|---|---|---|---|---|
| Coagulative Necrosis | Ischemic infarction of Heart, Kidney, Spleen (all solid organs EXCEPT brain) | Severe ischemia denatures structural proteins AND proteolytic enzymes simultaneously | Pale wedge-shaped infarct (kidney/spleen); preserved cell outlines ('ghost cells') without nuclei, deep eosinophilia | Red (hemorrhagic) infarcts occur in loose tissues with dual blood supply (lung, liver, bowel) or venous torsion (testis/ovary) |
| Liquefactive Necrosis | Brain ischemic stroke (MCA infarct) & Bacterial/fungal abscesses | Enzymatic digestion by microglial hydrolases (brain) or neutrophil lysosomal enzymes (abscess) | Soft liquid/creamy center; cystic cavity in brain surrounded by GFAP+ reactive astrocytic gliosis (scar) | Unlike myocardial infarction, CNS ischemic strokes undergo liquefactive necrosis and leave a permanent fluid-filled cyst on CT/MRI |
| Caseous Necrosis | Mycobacterium tuberculosis, Histoplasma, Coccidioides, Blastomyces | Delayed-type (Type IV) Th1/IFN-gamma macrophage activation walling off intracellular organisms | Gross white-yellow 'cottage cheese' center; amorphous pink granular debris surrounded by Langhans giant cells | Distinguish from Sarcoidosis and Crohn disease, which produce NON-caseating granulomas |
| Fat vs. Fibrinoid Necrosis | Fat: Acute pancreatitis / Breast trauma | Fibrinoid: Polyarteritis nodosa / Malignant HTN | Fat: Lipase releases free fatty acids -> Ca2+ saponification | Fibrinoid: Immune complexes + fibrin in arterial walls | Fat: Chalky-white areas, basophilic Ca2+ soap | Fibrinoid: Bright smudgy pink vessel wall on H&E | Fat necrosis in the breast after trauma (seatbelt injury) can calcify on mammography and mimic invasive breast carcinoma |
| Apoptosis (Intrinsic vs. Extrinsic) | Embryogenesis, endometrial shedding, CD8+ CTL killing, Viral hepatitis Councilman bodies | Intrinsic: BAX/BAK -> Cytochrome c -> Caspase-9 | Extrinsic: FasL/Fas or TNF -> Caspase-8 -> Caspase-3/7 | Cell shrinkage, pyknosis, eosinophilic apoptotic bodies, 180-bp DNA ladder, intact membrane, NO inflammation | Follicular lymphoma t(14;18) overexpresses anti-apoptotic BCL-2, preventing BAX/BAK pore formation and cytochrome c release |
Differentiating the Six Histopathologic Patterns of Necrosis
(1) Coagulative necrosis is the hallmark of acute ischemic infarction in all solid organs except the brain (heart, kidney, adrenal gland, spleen, liver); intracellular acidosis denatures both structural proteins and proteolytic enzymes, preserving the macroscopic wedge-shaped organ architecture and microscopic anucleate eosinophilic “ghost cell” outlines for several days until infiltrating neutrophils digest the debris. (2) Liquefactive necrosis occurs in central nervous system (brain) ischemic infarcts (due to high lipid content, abundant microglial lysosomal hydrolases, and minimal supportive stroma, resulting in a fluid-filled cystic cavity lined by reactive astrocytic gliosis) and in focal bacterial or fungal abscesses (where neutrophil elastase and collagenase liquefy tissue into creamy pus). (3) Caseous necrosis combines coagulative and liquefactive features in Mycobacterium tuberculosis and systemic endemic mycoses (Histoplasma, Coccidioides), producing a gross friable yellow-white “cheesy” center and microscopic structureless eosinophilic debris rimmed by epithelioid macrophages, Langhans multinucleated giant cells, and lymphocytes (caseating granuloma). (4) Fat necrosis follows enzymatic release of pancreatic lipases in acute pancreatitis or traumatic breast injury; liberated free fatty acids bind calcium ions via saponification, producing gross chalky-white deposits and microscopic shadowy adipocyte outlines with basophilic calcium deposits. (5) Fibrinoid necrosis occurs in immune-mediated vasculitis (Type III hypersensitivity such as polyarteritis nodosa), malignant hypertension, and preeclampsia, where immune complexes and plasma fibrin leak into vessel walls to create a bright pink, smudgy eosinophilic ring. (6) Gangrenous necrosis describes ischemic limb or bowel necrosis: dry gangrene is pure coagulative necrosis (mummified black toes in peripheral arterial disease), whereas wet gangrene occurs when superadded bacterial infection overlays liquefactive necrosis onto coagulative necrosis.
Intrinsic (Mitochondrial) vs. Extrinsic (Death Receptor) Apoptosis & Pyroptosis/Necroptosis
Apoptosis mediates physiological embryogenesis (regression of interdigital webs and Mullerian/Wolffian ducts), hormone-dependent involution (endometrial shedding during menses, lactating breast regression), thymic negative selection of autoreactive T cells, and cytotoxic CD8+ T-cell killing. In the Intrinsic (Mitochondrial) Pathway (triggered by DNA damage, p53 activation, growth-factor withdrawal, or misfolded ER stress), pro-apoptotic BH3-only sensors inhibit anti-apoptotic BCL-2 and BCL-xL, allowing BAX and BAK to oligomerize into outer mitochondrial membrane pores; leaked cytochrome c binds cytosolic Apaf-1 to activate initiator Caspase-9 (note: follicular lymphoma t(14;18) overexpresses BCL-2, immortalizing B cells by blocking cytochrome c release). In the Extrinsic (Death Receptor) Pathway, ligand binding of FasL (CD95L) to Fas (CD95) or TNF-alpha to TNFR1 recruits the FADD adapter domain to activate initiator Caspase-8 (mutations in Fas/FasL cause Autoimmune Lymphoproliferative Syndrome [ALPS] with massive lymphadenopathy, splenomegaly, and autoimmune cytopenias). Both pathways converge on executioner Caspase-3 and Caspase-7, which cleave the cytoskeleton and activate endonucleases that cleave internucleosomal DNA at 180-base-pair intervals (producing a characteristic “DNA ladder” on gel electrophoresis) while flipping phosphatidylserine to the outer membrane leaflet as an “eat-me” signal for macrophages.
Systemic & Localized Amyloidosis, Acute/Chronic Inflammation & Wound Healing
Amyloidosis encompasses a group of disorders in which soluble precursor proteins misfold into insoluble, extracellular beta-pleated sheet fibrils that deposit in vascular walls and parenchymal organs, causing pressure atrophy, restrictive cardiomyopathy, nephrotic syndrome, and hepatosplenomegaly. Regardless of the precursor protein, all amyloid deposits appear as amorphous, hyaline, salmon-pink extracellular material on H&E staining and demonstrate pathognomonic apple-green birefringence under polarized light when stained with Congo red.
Following tissue injury, the host mounts an acute inflammatory response (vascular dilation via histamine/prostaglandins, increased postcapillary venular permeability, neutrophil margination/extravasation peaking in the first 6–24 hours, followed by monocyte/macrophage replacement at 48–72 hours) that culminates in either complete resolution, abscess formation, chronic granulomatous inflammation, or connective-tissue wound healing and scar remodeling.
| Amyloid / Wound Entity | Precursor Protein / Mediator | Underlying Etiology | Target Organs & Clinical Manifestations | Pathologic & Therapeutic Pearl |
|---|---|---|---|---|
| AL (Primary) vs. AA (Secondary) Amyloidosis | AL: Ig Light Chains (lambda > kappa) | AA: Serum Amyloid A (SAA) | AL: Multiple Myeloma / Plasma cell dyscrasia | AA: Rheumatoid arthritis, IBD, Familial Mediterranean Fever | Nephrotic syndrome (proteinuria), restrictive cardiomyopathy, macroglossia, hepatosplenomegaly, periorbital purpura | Diagnose via abdominal fat-pad aspirate or rectal/renal biopsy showing Congo red apple-green birefringence |
| Dialysis vs. Transthyretin (ATTR) Amyloidosis | Dialysis: Beta-2-microglobulin | ATTR: Transthyretin (prealbumin) | Dialysis: Long-term hemodialysis | ATTR: Wild-type senile cardiac or autosomal dominant mutant TTR | Dialysis: Carpal tunnel syndrome & joint pain | ATTR: Restrictive cardiomyopathy (HFpEF) & peripheral neuropathy | Tafamidis stabilizes the transthyretin tetramer and reduces mortality in ATTR amyloid cardiomyopathy |
| Localized Amyloid Syndromes | A-beta (APP), Amylin (IAPP), Calcitonin, ANP | Alzheimer/Trisomy 21 (A-beta), Type 2 DM (IAPP), Medullary Thyroid Ca (Calcitonin), Aging atria (ANP) | Cerebral amyloid angiopathy (lobar hemorrhage) & plaques, pancreatic beta-cell loss, thyroid stromal amyloid | Medullary thyroid carcinoma originates from neural crest parafollicular C-cells and secretes calcitonin into amyloid stroma |
| Wound Healing Remodeling | Early: Type III collagen (days 3–5) -> Late: Type I collagen | TGF-beta (fibrosis), VEGF/FGF (angiogenesis), Zinc-dependent MMPs (collagenase), Vitamin C, Copper | Granulation tissue transitions to avascular collagenous scar reaching 70–80% maximum tensile strength at 3 months | Zinc deficiency delays Type III-to-Type I collagen remodeling and causes dysgeusia, alopecia, and periorificial pustular rash |
| Hypertrophic Scar vs. Keloid | Hypertrophic: Parallel Type III/I collagen | Keloid: Disorganized Type I & III collagen | Excessive TGF-beta fibroblast stimulation after thermal burns, piercings, or surgical incisions | Hypertrophic: Raised scar CONFINED to original wound margins | Keloid: Grows BEYOND wound borders (earlobes, sternum) | Keloids recur frequently after simple surgical excision; treat with intralesional triamcinolone (corticosteroid) injections |
Systemic (AL, AA, Dialysis, ATTR) vs. Localized (Alzheimer, Type 2 DM, Medullary Thyroid) Amyloidosis
Primary (AL) Amyloidosis results from clonal plasma cell dyscrasias (Multiple Myeloma or Waldenstrom macroglobulinemia) overproducing immunoglobulin light chains (most commonly lambda) that deposit as AL amyloid in the kidney (nephrotic syndrome, the #1 organ involved), heart (restrictive cardiomyopathy with low-voltage ECG and speckled interventricular septum on echocardiogram), tongue (macroglossia), periorbital skin (“pinch purpura”), and carpal tunnel. Secondary (AA) Amyloidosis complicates chronic inflammatory diseases (rheumatoid arthritis, inflammatory bowel disease, osteomyelitis, Familial Mediterranean Fever), where IL-6 drives hepatic synthesis of Serum Amyloid A (SAA) acute-phase reactant. Dialysis-related Amyloidosis occurs in end-stage renal disease patients on long-term hemodialysis due to failure to filter beta-2-microglobulin (the MHC Class I light chain), causing carpal tunnel syndrome and scapulohumeral arthropathy. Transthyretin (ATTR) Amyloidosis occurs as either a senile wild-type ATTR deposition in the ventricles of men >70 years old or a hereditary mutant ATTR polyneuropathy/cardiomyopathy (treated with the TTR-stabilizer tafamidis). Localized amyloid deposits include A-beta amyloid in cerebral plaques of Alzheimer disease (cleaved from APP on chromosome 21; explains why Down syndrome patients develop Alzheimer disease by age 40), Islet Amyloid Polypeptide (IAPP / amylin) in pancreatic beta-islets of Type 2 Diabetes Mellitus, Calcitonin (A-Cal) in the stroma of Medullary Thyroid Carcinoma (RET mutation), and Atrial Natriuretic Peptide (AANP) in isolated atrial amyloidosis causing atrial fibrillation.
Phases of Cutaneous Wound Healing, Collagen Remodeling & Keloid vs. Hypertrophic Scars
Cutaneous wound repair unfolds in three overlapping stages: (1) Inflammatory phase (Days 0–2): platelet plug hemostasis, PDGF/TGF-beta release, neutrophil debridement (24 hr), and macrophage recruitment (48–72 hr); (2) Proliferative / Granulation phase (Days 3–7): TGF-beta (the master fibrogenic cytokine), VEGF (angiogenesis), and FGF-2 stimulate fibroblasts to deposit loose Type III collagen and glycosaminoglycans alongside capillary buds, while myofibroblasts (expressing alpha-smooth muscle actin) contract the wound margins; and (3) Remodeling / Maturation phase (Weeks 1–52): zinc-dependent matrix metalloproteinases (MMPs / collagenases) degrade Type III collagen and replace it with cross-linked, high-tensile Type I collagen (requiring Vitamin C for prolyl/lysyl hydroxylation and Copper for lysyl oxidase cross-linking). At suture removal (1 week), wound tensile strength is only 10% of normal skin, ultimately plateauing at 70–80% of original skin strength by 3 months. Excessive collagen deposition produces either a Hypertrophic scar (parallel Type I/III collagen bundles that remain strictly confined within the original wound borders and often regress spontaneously) or a Keloid scar (disorganized, thick eosinophilic Type I and III collagen bundles produced via excessive TGF-beta signaling that grow wildly beyond the original wound borders in a claw-like pattern, preferentially affecting the earlobes, presternal chest, and deltoids of darker-skinned individuals, with high recurrence after excision).
Cell Cycle Regulation, Proto-Oncogenes & Tumor Suppressor Genes
Eukaryotic cell division progresses through G1 (presynthetic growth), S (DNA synthesis), G2 (premitotic check), and M (mitosis) phases, governed by cyclins complexed with cyclin-dependent kinases (CDKs). Cell types are stratified by proliferative capacity into Permanent cells (remain permanently in G0 and regenerate only via hypertrophy: cardiomyocytes, skeletal myocytes, and neurons), Stable (Quiescent) cells (reside in G0 but enter G1 upon injury or growth-factor stimulation: hepatocytes, proximal renal tubules, pancreatic acini, fibroblasts), and Labile cells (divide continuously from stem cells without entering G0: bone marrow hematopoietic cells, gut crypt epithelium, epidermis, hair follicles—explaining why chemotherapy causes myelosuppression, mucositis, and alopecia).
Neoplastic transformation requires clonal accumulation of driver mutations in two opposing gene classes: Proto-oncogenes (where a single-allele gain-of-function point mutation, chromosomal translocation, or gene amplification drives unregulated proliferation or blocks apoptosis) and Tumor Suppressor Genes (where biallelic loss-of-function—Knudson's Two-Hit Hypothesis—is required to disable cell-cycle checkpoints or DNA repair).
| Gene & Chromosome | Gene Class & Normal Function | Activating / Inactivating Mechanism | Associated Malignancies | Targeted Therapy / Clinical Pearl |
|---|---|---|---|---|
| TP53 (Chr 17p) & RB1 (Chr 13q) | Tumor Suppressors (G1/S checkpoint: p53 -> p21 inhibits CDK4 -> keeps Rb bound to E2F) | Biallelic loss of function (Knudson Two-Hit) or HPV E6 (degrades p53) & E7 (inhibits Rb) | Germline TP53 = Li-Fraumeni (SBLA); Germline RB1 = Bilateral Retinoblastoma & Osteosarcoma | TP53 is mutated in >50% of all human cancers; HPV 16/18 E6 and E7 drive cervical and oropharyngeal SCC |
| KRAS, BRAF & BCR-ABL | Proto-Oncogenes (Intracellular signal transducers) | KRAS: Loss of GTPase activity | BRAF: V600E mutation | BCR-ABL: t(9;22) translocation | KRAS: Pancreatic (90%), Colon, Lung | BRAF: Melanoma, Hairy cell leukemia | BCR-ABL: CML, ALL | Imatinib inhibits BCR-ABL (and c-KIT in GIST); Vemurafenib + Trametinib (MEK inhibitor) treats BRAF V600E melanoma |
| c-MYC, BCL-2 & Cyclin D1 | Proto-Oncogenes (Transcription factor, Anti-apoptotic, Cell-cycle regulator) | Chromosomal translocations next to heavy-chain Ig locus (Chr 14) | t(8;14) c-MYC = Burkitt lymphoma | t(14;18) BCL-2 = Follicular lymphoma | t(11;14) Cyclin D1 = Mantle cell lymphoma | Venetoclax directly inhibits BCL-2 to restore intrinsic mitochondrial apoptosis in CLL and lymphomas |
| HER2 (ERBB2), RET & KIT | Proto-Oncogenes (Receptor Tyrosine Kinases) | HER2: Gene amplification | RET & KIT: Activating point mutations | HER2: Breast & gastric adenocarcinoma | RET: MEN 2A/2B (Medullary thyroid + Pheo) | KIT: GIST | Trastuzumab (Herceptin) targets HER2 (monitor LVEF for reversible cardiotoxicity) |
| APC (Chr 5q) & VHL (Chr 3p) | Tumor Suppressors (Beta-catenin destruction & HIF-1a ubiquitin ligase) | Biallelic loss of function (Two-Hit hypothesis) | APC: Familial Adenomatous Polyposis (FAP), Gardner syndrome, Turcot syndrome | VHL: Hemangioblastoma + Clear cell RCC | Gardner syndrome = FAP + osteomas + desmoid tumors + congenital hypertrophy of retinal pigment epithelium |
The G1/S Restriction Checkpoint: p53, p21, CDK4/Cyclin D, Retinoblastoma (Rb) & E2F
The G1-to-S transition is the master restriction point of the cell cycle. In quiescent cells, hypophosphorylated Retinoblastoma protein (Rb) tightly binds and sequesters the transcription factor E2F, blocking S-phase gene expression. Mitogenic growth factors stimulate synthesis of Cyclin D, which complexes with CDK4 and CDK6 (followed by Cyclin E/CDK2) to hyperphosphorylate Rb; phosphorylated Rb releases active E2F, driving transcription of DNA polymerase, thymidine kinase, and S-phase entry. When DNA damage or hypoxia is detected, the tumor suppressor p53 (“guardian of the genome”, encoded on chromosome 17p) is stabilized (escaping MDM2 ubiquitin degradation) and transcriptionally upregulates p21, a potent CDK inhibitor that blocks Cyclin D/CDK4 phosphorylation of Rb—halting the cell in G1 to allow DNA repair. If DNA repair fails, p53 activates BAX to trigger intrinsic mitochondrial apoptosis. High-risk Human Papillomavirus (HPV types 16 and 18) drives cervical, anal, and oropharyngeal squamous cell carcinoma via two viral oncoproteins: E6 promotes ubiquitin-mediated proteasomal degradation of p53, and E7 binds and inactivates Rb (liberating E2F).
High-Yield Proto-Oncogenes vs. Hereditary Tumor Suppressor Syndromes (Rb, Li-Fraumeni, APC)
Proto-oncogenes fall into five functional categories: (1) Growth factors (PDGFB in astrocytoma), (2) Receptor Tyrosine Kinases (HER2/ERBB2 amplification in breast/gastric cancer [targeted by trastuzumab]; RET point mutation in MEN 2A/2B and medullary thyroid cancer; EGFR and ALK in lung adenocarcinoma; KIT [CD117] in gastrointestinal stromal tumors [GIST, targeted by imatinib]), (3) Signal Transducers (KRAS GTPase point mutation in colon, pancreatic, and lung cancers; BRAF V600E serine/threonine kinase mutation in melanoma, hairy cell leukemia, and papillary thyroid cancer [targeted by vemurafenib]; BCR-ABL t(9;22) Philadelphia chromosome in CML; JAK2 V617F in polycythemia vera, essential thrombocythemia, and primary myelofibrosis), (4) Nuclear Transcription Factors (c-MYC t(8;14) in Burkitt lymphoma; N-MYC amplification in neuroblastoma; L-MYC in small cell lung cancer), and (5) Cell-Cycle/Apoptosis Regulators (Cyclin D1 t(11;14) in mantle cell lymphoma; BCL-2 t(14;18) in follicular lymphoma). Conversely, germline inheritance of one mutant tumor suppressor allele produces autosomal dominant cancer predisposition syndromes when the second wild-type allele is lost somatically: germline RB1 (Chr 13q14) mutation causes bilateral retinoblastoma (leukocoria) and osteosarcoma; germline TP53 (Chr 17p) mutation causes Li-Fraumeni Syndrome (SBLA: Sarcoma, Breast, Leukemia, Adrenal cortical carcinoma, and Brain tumors); and germline APC (Chr 5q) mutation causes Familial Adenomatous Polyposis (FAP) (>100–1,000 colonic polyps with 100% progression to colon cancer by age 40 via the APC → KRAS → p53 adenoma-carcinoma sequence).
Hallmarks of Cancer, Invasion Cascade, Grading vs. Staging & Tumor Markers
Malignant neoplasms acquire self-sufficiency in growth signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless replicative potential via telomerase upregulation (preventing telomere shortening), sustained angiogenesis via VEGF and FGF, metabolic reprogramming toward aerobic glycolysis (the Warburg effect, which shunts glucose into lactate and biosynthetic intermediates even in the presence of abundant oxygen—exploited clinically by 18F-FDG PET/CT imaging), and immune evasion via PD-L1 expression (which binds T-cell PD-1 receptors to exhaust cytotoxic CD8+ T cells—reversed by immune checkpoint inhibitors pembrolizumab, nivolumab, and ipilimumab [anti-CTLA-4]).
The metastatic cascade requires four sequential steps as carcinoma in situ breaches the epithelial basement membrane: (1) Detachment of tumor cells from one another via downregulation of E-cadherin (canonical in diffuse signet-ring gastric carcinoma and invasive lobular breast carcinoma), (2) Attachment to laminin and fibronectin in the basement membrane, (3) Degradation of Type IV collagen in the basement membrane via Type IV collagenases (MMP-2 and MMP-9), and (4) Migration into lymphatic or hematogenous channels.
| Diagnostic Marker / Pathway | Lineage / Molecular Target | Primary Associated Malignancies | Clinical Utility & Metastatic Pattern | Board Exam High-Yield Trap |
|---|---|---|---|---|
| E-Cadherin Loss & MMP-2/MMP-9 | Cell-cell adhesion (E-cadherin) & Type IV collagenase (MMPs) | Invasive Lobular Breast Carcinoma & Diffuse (Signet-Ring / Linitis Plastica) Gastric Cancer | Step 1 of invasion is loss of E-cadherin; Step 3 is MMP degradation of Type IV basement membrane collagen | Germline CDH1 (E-cadherin) mutation causes hereditary diffuse gastric cancer AND lobular breast cancer |
| IHC Intermediate Filaments | Cytokeratin, Vimentin, Desmin, GFAP, S-100 | Carcinoma (Cytokeratin), Sarcoma (Vimentin), Muscle (Desmin), Glia/GBM (GFAP), Neural Crest/Melanoma (S-100) | Classifies poorly differentiated anaplastic metastases of unknown primary origin | Glioblastoma (astrocyte) is GFAP-positive; Brain metastases (lung/breast/melanoma) are multiplex nodules at the gray-white junction |
| Serum Tumor Markers (AFP, hCG, LDH) | Oncofetal proteins & intracellular enzymes | AFP: Hepatocellular Ca, Yolk Sac (Endodermal Sinus) Tumor | hCG: Choriocarcinoma, Hydatidiform mole, Seminoma (10%) | Monitors recurrence after surgical resection or chemotherapy | Pure Testicular Seminoma has elevated placental ALP and LDH (and sometimes mild beta-hCG), NEVER elevated AFP |
| CA 19-9, CA-125, CEA & Calcitonin | Mucin glycoproteins, carcinoembryonic antigen, C-cell hormone | CA 19-9: Pancreatic adenocarcinoma | CA-125: Epithelial ovarian cancer | CEA: Colorectal/pancreatic | Calcitonin: Medullary thyroid | Tracks therapeutic response and post-operative relapse | CEA and CA-125 lack sensitivity/specificity for asymptomatic population screening (elevated in smoking, IBD, endometriosis) |
| Organ Metastasis Tropism | Portal vein -> Liver (#1 site of GI metastasis); Caval veins -> Lungs | Colon/Pancreas -> Liver | Sarcomas/RCC/Choriocarcinoma -> Lung | Prostate/Breast/Lung -> Bone | Metastatic tumors are far more common than primary tumors in the Liver, Lung, Brain, and Bone | Prostate adenocarcinoma produces OSTEOBLASTIC (blastic/sclerotic) vertebral metastases; Multiple Myeloma is purely OSTEOLYTIC |
Tumor Grading vs. TNM Staging & Hematogenous vs. Lymphatic Metastatic Tropism
Tumor Grade is a microscopic histopathologic assessment of cellular differentiation, nuclear pleomorphism, and mitotic index (Grade 1 well-differentiated to Grade 4 anaplastic/undifferentiated), whereas Tumor Stage (TNM) is an anatomical/clinical assessment of spread and carries far greater prognostic value than grade: T (size and depth of invasion of the primary tumor), N (regional lymph node metastasis—the single most important prognostic factor in breast and colon cancer), and M (distant organ metastasis—the single most important overall TNM determinant of survival). Carcinomas generally spread first via lymphatics (save for 4 classic carcinomas that spread hematogenously via veins: Renal Cell Carcinoma [invades the renal vein and IVC], Hepatocellular Carcinoma [invades the hepatic/portal veins], Follicular Thyroid Carcinoma, and Choriocarcinoma), whereas Sarcomas spread almost exclusively via the hematogenous (venous) route to the lungs. The four most common primary tumors that metastasize to bone are Prostate, Breast, Lung, and Thyroid/Kidney (where Prostate cancer produces uniquely osteoblastic [sclerotic] bone metastases, while lung, thyroid, and renal cancers produce osteolytic lesions).
Immunohistochemical Stains & Serum Tumor Markers
When a poorly differentiated metastatic tumor of unknown primary is biopsied, immunohistochemical (IHC) intermediate filament staining identifies the lineage of origin: Cytokeratin marks epithelial Carcinomas; Vimentin marks mesenchymal Sarcomas; Desmin marks myogenic tumors (rhabdomyosarcoma, leiomyosarcoma); GFAP (Glial Fibrillary Acidic Protein) marks neuroglial tumors (astrocytoma, glioblastoma, ependymoma); Neurofilament marks neuronal tumors (neuroblastoma, pheochromocytoma); S-100 marks neural crest derivatives (Melanoma, Schwannoma, Langerhans cell histiocytosis); and CD45 (Leukocyte Common Antigen) marks Lymphomas/Leukemias. Serum tumor markers (PSA, CEA, CA 19-9, CA-125, AFP, beta-hCG, calcitonin) are used primarily to monitor treatment response and detect post-resection recurrence rather than for standalone population screening.
Paraneoplastic Syndromes, Cancer Cachexia & Oncogenic Microbes
Paraneoplastic syndromes are systemic clinical manifestations in cancer patients that cannot be explained by local tumor invasion, distant metastasis, or elaboration of hormones indigenous to the tissue of origin; instead, they arise from ectopic peptide hormone secretion or cross-reactive antineuronal/neuromuscular autoantibodies. Up to 10–15% of cancer patients develop a paraneoplastic syndrome, which frequently represents the earliest presenting sign of an occult malignancy or mimics metastatic disease.
In parallel, cancer cachexia—characterized by profound loss of both skeletal muscle mass and adipose tissue that cannot be reversed by nutritional supplementation alone—is mediated by tumor- and macrophage-derived TNF-alpha (cachectin), IL-1, IL-6, and IFN-gamma, which activate the ubiquitin-proteasome pathway in skeletal muscle and lipoprotein lipase inhibition in adipocytes.
| Paraneoplastic / Oncogenic Syndrome | Mediating Hormone / Antibody / Pathogen | Primary Underlying Malignancy | Signature Clinical & Lab Findings | Key Board Distinction |
|---|---|---|---|---|
| Hypercalcemia of Malignancy | Parathyroid Hormone-Related Peptide (PTHrP) or 1,25-(OH)2-Vitamin D | Squamous Cell Carcinoma of Lung, Renal Cell Carcinoma, Breast Ca, Hodgkin/HTLV-1 Lymphoma | Stones, bones, groans, psychiatric overtones; HIGH Ca2+, LOW phosphate, SUPPRESSED intact PTH | Distinguish from Primary Hyperparathyroidism, in which both serum Ca2+ AND intact PTH are elevated |
| SIADH & Ectopic Cushing Syndrome | Ectopic ADH (vasopressin) vs. Ectopic ACTH | Small Cell Lung Carcinoma (SCLC; neuroendocrine Kulchitsky cells) | SIADH: Euvolemic hyponatremia, urine Na+ >40 | Ectopic ACTH: Rapid weight loss, severe hypokalemic alkalosis, high cortisol | High-dose dexamethasone fails to suppress cortisol in ectopic ACTH from SCLC (suppresses >50% in pituitary Cushing disease) |
| Lambert-Eaton (LEMS) vs. Myasthenia Gravis | LEMS: Anti-presynaptic P/Q-type VGCC | MG: Anti-postsynaptic nicotinic AChR | LEMS: Small Cell Lung Carcinoma | MG: Anterior mediastinal Thymoma | LEMS: Proximal hip/shoulder weakness + hyporeflexia + dry mouth that IMPROVES with repeated use | MG: Ptosis/diplopia that WORSENS with use | High-frequency repetitive nerve stimulation increases compound muscle action potential amplitude in LEMS (decreases in MG) |
| Opsoclonus-Myoclonus & Anti-NMDA Encephalitis | Autoantibodies against intracellular/synaptic neuronal antigens | Neuroblastoma (pediatric) & Ovarian Teratoma (anti-NMDA receptor) | Opsoclonus-myoclonus ('dancing eyes, dancing feet') in child with abdominal mass; Psychosis + seizures + autonomic instability in young woman | Always perform pelvic ultrasound/MRI for ovarian teratoma in a young female presenting with acute psychosis and seizures |
| Oncogenic Pathogens (EBV, H. pylori, Schistosoma, Clonorchis) | Viral oncoproteins or chronic mucosal inflammation | EBV: Burkitt/Nasopharyngeal | H. pylori: Gastric MALToma | S. haematobium: Bladder SCC | Clonorchis: Cholangiocarcinoma | Painless hematuria in Egyptian farmer -> S. haematobium calcified bladder wall -> Squamous cell bladder cancer | Early-stage H. pylori-positive gastric MALT lymphoma regresses completely with antibiotic + PPI eradication therapy alone |
Endocrine & Hematologic Paraneoplastic Syndromes by Tumor Histology
Lung carcinomas are the supreme board prototypes for paraneoplastic differentiation: Squamous Cell Carcinoma of the lung (central, cavitary mass with keratin pearls and intercellular bridges in a smoker) secretes Parathyroid Hormone-Related Peptide (PTHrP), causing humoral hypercalcemia of malignancy (elevated Ca2+, low phosphate, and suppressed endogenous PTH; also seen in clear cell renal cell carcinoma and adult T-cell leukemia/lymphoma). Conversely, Small Cell Lung Carcinoma (SCLC) (central neuroendocrine tumor of Kulchitsky cells, chromogranin/synaptophysin-positive, N-MYC amplified) causes three classic paraneoplastic syndromes: (1) SIADH via ectopic ADH secretion (euvolemic hyponatremia with inappropriately concentrated urine osmolality >100 mOsm/kg), (2) Cushing syndrome via ectopic ACTH secretion (hypertension, hypokalemic metabolic alkalosis, hyperglycemia, and hyperpigmentation without dexamethasone suppression), and (3) Lambert-Eaton Myasthenic Syndrome (LEMS) via autoantibodies against presynaptic P/Q-type voltage-gated calcium channels (causing proximal limb weakness and autonomic dry mouth that improves with repeated muscle contraction, unlike Myasthenia Gravis which is associated with Thymoma and worsens with repetition). Polycythemia (ectopic erythropoietin [EPO]) is classically caused by Renal Cell Carcinoma, Hepatocellular Carcinoma, Cerebellar Hemangioblastoma (VHL), Pheochromocytoma, and Uterine Leiomyoma. Mucin-producing adenocarcinomas (especially pancreatic, gastric, and lung adenocarcinoma) cause migratory superficial thrombophlebitis (Trousseau syndrome) and nonbacterial thrombotic (marantic) endocarditis.
Oncogenic Viruses, Bacteria & Helminths
Infectious pathogens account for 15% of global malignancies via chronic inflammation or viral oncoprotein expression: Epstein-Barr Virus (EBV / HHV-4) drives endemic/sporadic Burkitt lymphoma, Hodgkin lymphoma (Reed-Sternberg cells), nasopharyngeal carcinoma, and primary CNS lymphoma in AIDS; Human Herpesvirus 8 (HHV-8) drives Kaposi sarcoma (spindle-cell vascular tumor in HIV/transplant patients) and primary effusion lymphoma; Hepatitis B and C viruses (along with Aspergillus flavus aflatoxin B1, which induces a G-to-T transversion at codon 249 of TP53) drive hepatocellular carcinoma; HTLV-1 causes Adult T-Cell Leukemia/Lymphoma (flower-like nuclei + hypercalcemia); Helicobacter pylori causes gastric adenocarcinoma and gastric MALT lymphoma (reversible with triple/quadruple antibiotic eradication!); Schistosoma haematobium causes Squamous Cell Carcinoma of the urinary bladder in Middle Eastern/Egyptian patients (whereas smoking and aniline dyes cause urothelial transitional cell carcinoma); and the liver flukes Clonorchis sinensis and Opisthorchis viverrini cause cholangiocarcinoma.
Osteopathic Considerations & Absolute Contraindications in Oncology & Paraneoplastic Care
- All solid-organ ischemic infarcts (heart, kidney, spleen, liver) undergo COAGULATIVE necrosis (preserving ghost-cell outlines), EXCEPT ischemic infarction of the BRAIN, which undergoes LIQUEFACTIVE necrosis and leaves a fluid-filled cystic cavity lined by GFAP-positive astrocytic gliosis.
- Never confuse Squamous Cell and Small Cell Lung Carcinoma paraneoplastics: Central Squamous Cell Carcinoma causes HYPERCALCEMIA via PTHrP (low intact PTH), whereas Central Small Cell Carcinoma causes SIADH (hyponatremia), Ectopic ACTH (Cushing syndrome), and Lambert-Eaton syndrome.
- Differentiate Lambert-Eaton Myasthenic Syndrome (LEMS) from Myasthenia Gravis (MG): LEMS (Small Cell Lung Cancer; presynaptic Ca2+ channel antibodies) presents with proximal limb weakness and autonomic symptoms that IMPROVE with repeated muscle contraction, whereas MG (Thymoma; postsynaptic AChR antibodies) presents with ocular ptosis/diplopia and bulbar weakness that WORSEN with repeated use.
- In amyloidosis, Congo red staining of an abdominal fat-pad aspirate or rectal/renal biopsy demonstrates pathognomonic apple-green birefringence under polarized light; AL amyloid derives from immunoglobulin light chains (Multiple Myeloma), whereas AA amyloid derives from Serum Amyloid A in chronic inflammatory disorders (RA, IBD, Familial Mediterranean Fever).
- Distinguish Keloid from Hypertrophic scars: both result from excessive TGF-beta-driven fibroblast collagen deposition, but a Hypertrophic scar remains strictly confined within the original wound boundaries, whereas a Keloid (disorganized Type I and III collagen) grows wildly beyond the original wound borders.
- Remember the four carcinomas that spread HEMATOGENOUSLY (via veins) rather than lymphatically: Renal Cell Carcinoma (invades renal vein/IVC), Hepatocellular Carcinoma (invades hepatic/portal vein), Follicular Thyroid Carcinoma, and Choriocarcinoma.